GRIA2 and glioblastoma: In particular, a comparative study reported that ADAR3 could compete with ADAR2 for binding to glutamate receptor ionotropic AMPA 2 (GRIA2) mRNA, inhibiting ADAR2-catalyzed A-to-I editing at the Q/R site of GRIA2 in glioblastoma [166].